Registration & abstract submissions are OPEN!
Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC
Registration & abstract submissions are OPEN!
Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC
Welcome @medsir.bsky.social
@rcsi.bsky.social #LCSM
Welcome @medsir.bsky.social
@rcsi.bsky.social #LCSM
#EuropeLung #ERS #LungAmbition #RCSI #LCSM
#EuropeLung #ERS #LungAmbition #RCSI #LCSM
Complete this short set of q’s on irAE care in your institution & country: vub.fra1.qualtrics.com/jfe/form/SV_...
@oncoalert.bsky.social
Complete this short set of q’s on irAE care in your institution & country: vub.fra1.qualtrics.com/jfe/form/SV_...
@oncoalert.bsky.social
A snapshot of members & the important themes fostered this year: community, leadership, support 🌍
Watch this space for new creative content & events in 2025 🏆 @elinardou.bsky.social @solangepeters.bsky.social
A snapshot of members & the important themes fostered this year: community, leadership, support 🌍
Watch this space for new creative content & events in 2025 🏆 @elinardou.bsky.social @solangepeters.bsky.social
Proffered paper🔥
Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social
- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal
Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky
Proffered paper🔥
Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social
- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal
Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky
Proffered paper🔥
Gut microbiome in Ph III NIPPON trial (N/I/chemo v Pembro/chemo 1L) #JCOG
- Fusicatenibacter, Butyricicoccus = ⬆️ OS (esp with N+I: HR 0.56, 0.52) & ⬇️severe irAEs
- Blautia = ⬆️OS
- Prevotella species = ⬇️OS with N+I
@oncoalert.bsky.social #MedSky #OncSky #LCSM
Proffered paper🔥
Gut microbiome in Ph III NIPPON trial (N/I/chemo v Pembro/chemo 1L) #JCOG
- Fusicatenibacter, Butyricicoccus = ⬆️ OS (esp with N+I: HR 0.56, 0.52) & ⬇️severe irAEs
- Blautia = ⬆️OS
- Prevotella species = ⬇️OS with N+I
@oncoalert.bsky.social #MedSky #OncSky #LCSM
@mskcancercenter.bsky.social reunion!
Welcome @adamjschoenfeld.bsky.social & #AlexShoushtari. Great talks on advances in cell therapy for NSCLC & melanoma, at the Gathering around Cancer in Dublin ☘️
@mskcancercenter.bsky.social #RoisinOCearbhail #MeganGreally #JohnMcCaffrey
@mskcancercenter.bsky.social reunion!
Welcome @adamjschoenfeld.bsky.social & #AlexShoushtari. Great talks on advances in cell therapy for NSCLC & melanoma, at the Gathering around Cancer in Dublin ☘️
@mskcancercenter.bsky.social #RoisinOCearbhail #MeganGreally #JohnMcCaffrey
Superb 🇮🇪young investigator session at the Gathering in Cancer meeting, in Dublin today:
- ctDNA in NSCLC @davidoreilly.bsky.social #beaumontrcsi
- melanoma #SarahLochrin #mskcc
- GI cancer #TimOBrien
- oncogene+ NSCLC @drdavidmcmahon.bsky.social
- HCC #harryharvey
Well done all🏆
Superb 🇮🇪young investigator session at the Gathering in Cancer meeting, in Dublin today:
- ctDNA in NSCLC @davidoreilly.bsky.social #beaumontrcsi
- melanoma #SarahLochrin #mskcc
- GI cancer #TimOBrien
- oncogene+ NSCLC @drdavidmcmahon.bsky.social
- HCC #harryharvey
Well done all🏆
Key points:
- PCI optional in ES SCLC IO trials
- MRI surveillance acceptable in non IO era
- in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms
#LCSM #MedSky #OncSky
www.sciencedirect.com/science/arti...
Key points:
- PCI optional in ES SCLC IO trials
- MRI surveillance acceptable in non IO era
- in LS SCLC, Adriatic showed PCI beneficial in IO & non IO arms
#LCSM #MedSky #OncSky
www.sciencedirect.com/science/arti...